All News
Filter News
Found 6,918 articles
-
Late Thursday, ArriVent Biopharma announced its upsized initial public offering to support the development of its EGFR inhibitor furmonertinib, following CG Oncology going public earlier in the day.
-
ArriVent Announces Pricing of Upsized Initial Public Offering - Jan 26, 2024
1/26/2024
ArriVent BioPharma, Inc. announced the pricing of its upsized initial public offering of 9,722,222 shares of its common stock at a public offering price of $18.00 per share.
-
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
1/26/2024
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the closing of its initial public offering of 2,234,222 shares of common stock priced at $5.00 per share.
-
The bladder cancer-focused company’s larger-than-expected Nasdaq debut on Thursday opens this year’s batch of planned initial public offerings, which include at least half a dozen biotechs.
-
BrightSpring Health Services Announces Pricing of its Initial Public Offering and Concurrent Offering of Tangible Equity Units
1/25/2024
BrightSpring Health Services, Inc. (“BrightSpring” or “BrightSpring Health Services”) today announced the pricing of an initial public offering of 53,333,334 shares of its common stock at $13.00 per share and a concurrent offering of 8,000,000 of its 6.75% tangible equity units (“Units”), with a stated amount of $50.00 per Unit.
-
CG Oncology Announces Pricing of Upsized Initial Public Offering
1/24/2024
CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its upsized initial public offering of 20,000,000 shares of its common stock at an initial public offering price of $19.00 per share.
-
With initial public offering activity continuing to gain momentum in early 2024, ArriVent Biopharma in a Monday SEC filing laid out the company’s plans to go public.
-
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
1/22/2024
60 Degrees Pharmaceuticals, Inc. announced that, following a Type C meeting held on January 17, 2024 with the US Food and Drug Administration, the Company will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S.
-
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
1/22/2024
Abivax SA, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, provides an outlook on its 2024 strategic priorities and milestones.
-
The blank check company Thursday filed with the SEC for the initial public offering. While a specific business for Helix Acquisition Corp. II has not yet been identified, the fund will target biotech.
-
Bowen Acquisition Corp Announces Entering into Merger Agreement with Shenzhen Qianzhi BioTech Company
1/19/2024
Bowen Acquisition Corp, a special purpose acquisition company, announced the execution of an agreement and plan of merger with Shenzhen Qianzhi BioTechnology Co., Ltd, a biotech company engaged in development, manufacturing and sales of ozonated health and wellness products in China.
-
The bladder cancer-focused biotech is looking to be one of the first companies out of the gate with an initial public offering in 2024.
-
Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.
-
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements - Jan 16, 2024
1/16/2024
60 Degrees Pharmaceuticals, Inc. announced that on January 10, 2024 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC stating the Company has regained compliance with the minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
-
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
1/16/2024
Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients in the Special Issue Gliomas: Signaling Pathways, Molecular Mechanisms and Therapeutic Approaches.
-
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
1/12/2024
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced restructuring.
-
SeaStar Medical Appoints David A. Green as Chief Financial Officer
1/11/2024
SeaStar Medical Holding Corporation announces the appointment of healthcare industry veteran David A. Green as Chief Financial Officer, effective January 10, 2024.
-
The IPO window is starting to crack open this year, with Metagenomi and ArriVent making their offerings ahead of the J.P. Morgan Healthcare Conference.
-
Sage Therapeutics Announces Changes to Board of Directors - Jan 08, 2024
1/8/2024
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced the retirement of Kevin Starr from the company’s board of directors.
-
While initial public offering activity was light in 2023, the new year has recorded the first IPO plan—from California-based CG Oncology.